Clinical trials: Febrile Neutropenia (FN)
Cancer in Children/Adolescents, Fever in Neutropenia
Pediatric FN Definition 2012 Bern
STUDY AIMS Based on prospectively collected information on ear temperatures, ANC values, emergency calls and consultations for fever, and on hospitalizations for FN in children and adolescents with cancer to describe the…
- Trial name
- NCT01683370
- Where
- Switzerland
- Volunteers
- 39 people
- Sponsor
- Dr. Roland Ammann
Bloodstream Infection, Gram Negative Infections
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients
The goal of this clinical trial is to learn if a personalized duration of antibiotic therapy, based on clinical stability, is as effective as a standard duration of at least 10 days in hospitalized patients with hematologic…
- Conditions
- Bloodstream Infection, Gram Negative Infections, Bacteraemia Caused by Gram-Negative Bacteria, Febrile Neutropenia (FN)
- Trial name
- PERaSTrA (NCT07372131)
- Testing
- Clinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration
- Where
- Italy
- Volunteers
- 172 people
- Sponsor
- Valeria Cento
Febrile Neutropenia (FN), Sepsis
Prophylaxis of Febrile Neutropenia With Lactoferrin in Oncohematologic Children Undergoing Induction Chemotherapy
Test, in a randomized phase II trial, the safety and efficacy of lactoferrin prophylaxis in preventing the occurrence of febrile neutropenia and sepsis, with particular regard to forms due to multidrug-resistant Gram-negative…
- Conditions
- Febrile Neutropenia (FN), Sepsis, Chemotherapy Treatment
- Trial name
- Lactoferrin (NCT07113314)
- Testing
- Lactoferrin Bovine
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cancer, Pediatrics
SPOG 2015 FN Definition. A Multi-center Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia
In a multi-center open-label cluster-randomized controlled parallel-group multiple crossover non-inferiority trial in children and adolescents up to 20 years diagnosed with cancer requiring chemotherapy, primarily the safety, and…
- Conditions
- Cancer, Pediatrics, Fever, Neutropenia
- Trial name
- NCT02324231
- Testing
- 39.0°C temperature limit defining fever, 38.5°C temperature limit defining fever
- Where
- 6 sites in Switzerland
- Volunteers
- 269 people
- Sponsor
- Swiss Pediatric Oncology Group
Febrile Neutropenia
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
This clinical study is a multiple center, registering and real-world conditional research. The breast cancer patients planning for chemotherapy evaluated with medium-high risk of febrile neutropenia (FN) are recruited, receiving…
- Trial name
- NCT03618810
- Testing
- PEGCSF first level prophylactic use, PEGCSF second level prophylactic use
- Volunteers
- 2,000 people
- Sponsor
- Zhejiang Cancer Hospital
Chemotherapy-induced Neutropenia
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
The present study was an observational, multicenter, non-interventional, single arm, open label, PMS study conducted in Iran. The primary objective of this study was safety assessment, including the rate of AEs.
- Trial name
- NCT04460079
- Testing
- Peg-filgrastim
- Volunteers
- 654 people
- Sponsor
- Cinnagen
Febrile Neutropenia, Non-myeloid Malignancy
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
This is a multicenter, prospective, observational cohort registry in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy who are considered to be at high risk for developing febrile neutropenia (FN).
- Trial name
- POEM (NCT04662892)
- Testing
- Pegfilgrastim-Cbqv
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Coherus Oncology, Inc.
Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
The study is being conducted to evaluate the preference, and safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of chemotherapy-related moderate to severe neutropenia of Patients with nonmyeloid malignancies.
- Trial name
- NCT06254742
- Testing
- HHPG-19K Injection
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
The purpose of this study is to try to find a better injection regimen (including time and dose) of PEG-rhG-CSF, which is supposed to better prevent bone marrow suppression and/or FN in breast cancer patients who receive…
- Trial name
- NCT04477616
- Testing
- Day 7 regimen, Day 3 regimen
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Mycoses, Candidiasis
A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection
The purpose of this study is to assess the pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time) of itraconazole (ITCZ) oral solution in participants…
- Conditions
- Mycoses, Candidiasis, Aspergillosis, Cryptococcosis
- Trial name
- NCT00784368
- Testing
- ITCZ Oral Solution, ITCZ-IV
- Where
- Japan
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutical K.K.
Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN)
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA.
- Conditions
- Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN), Neutropenia
- Trial name
- NCT07724756
- Testing
- Albipagrastim alf
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Infections, Hematologic Diseases
mNGS Versus Blood Culture in FN
Blood stream infection (BSI) during febrile neutropenia (FN) is a lethal complication, while confirmed diagnosis via blood culture is usually with low sensitivity and time delay.
- Conditions
- Infections, Hematologic Diseases, Febrile Neutropenia
- Trial name
- NCT05149547
- Testing
- blood culture versus mNGS detection
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Chemotherapy-induced Febrile Neutropenia
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
To estimate the incidence of febrile neutropenia in patients with breast cancer and non-Hodgkin's lymphoma receiving high (> 20%) FN-risk chemotherapy and pegfilgrastim primary prophylaxis.
- Trial name
- NCT02178475
- Where
- 74 sites in Austria, Belgium and 7 more
- Volunteers
- 943 people
- Sponsor
- Amgen
Solid Tumors, Malignant Hemopathy
Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.
- Conditions
- Solid Tumors, Malignant Hemopathy, Chemotherapy-induced Febrile Neutropenia (FN)
- Trial name
- NCT01574235
- Testing
- Nivestim®
- Where
- 87 sites in France
- Volunteers
- 2,114 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Breast Cancer, Chemotherapy-Induced Neutropenia
Correlation Between ANC and Bone Pain in Breast Cancer Patients Receiving Long-Acting G-CSF
This prospective, multicenter, non-randomized controlled study aims to evaluate bone pain associated with prophylactic use of long-acting granulocyte colony-stimulating factors (G-CSFs) in patients with breast cancer receiving…
- Conditions
- Breast Cancer, Chemotherapy-Induced Neutropenia, Febrile Neutropenia, Bone Pain
- Trial name
- Bone Pain (NCT07806084)
- Volunteers
- 132 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Febrile Neutropenia (FN), Pediatric Cancer
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker…
- Conditions
- Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors
- Trial name
- E-STOP2 (NCT07590648)
- Testing
- Early Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy
- Where
- 4 sites in Spain
- Volunteers
- 136 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Non-Myeloid Malignancy
Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy
This phase 3 study is aimed to evaluate the safety and efficacy of YPEG-rhG-CSF in reducing the infection manifested by febrile neutropenia in patients with non-myeloid malignancy who receiving Myelosuppressive Chemotherapy which…
- Trial name
- NCT04466137
- Testing
- YPEG-rhG-CSF, rhG-CSF/PEG-rhG-CSF
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult
- Trial name
- G-CSF in NHL (NCT06665737)
- Testing
- Early receiving G-CSF group, Late receiving G-CSF group
- Where
- 3 sites in Thailand
- Volunteers
- 126 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Non Small Cell Lung Cancer
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in NSCLC patients at risk of platinum-containing…
- Trial name
- NCT06143735
- Testing
- Efgbemalenograstim alfa
- Where
- 10 sites in China
- Volunteers
- 99 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Efbemalenograstim alfa for primary/secondary prevention in patients with solid tumors at high risk for febrile neutropenia (FN) or Intermediate risk of chemotherapy regimens associated with other risk factors in FN
- Conditions
- Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
- Trial name
- NCT07187908
- Testing
- Efbemalenograstim alfa Injection
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Henan Cancer Hospital